[go: up one dir, main page]

WO2024035929A3 - Insulin sensitizers for reversal of insulin resistance - Google Patents

Insulin sensitizers for reversal of insulin resistance Download PDF

Info

Publication number
WO2024035929A3
WO2024035929A3 PCT/US2023/030076 US2023030076W WO2024035929A3 WO 2024035929 A3 WO2024035929 A3 WO 2024035929A3 US 2023030076 W US2023030076 W US 2023030076W WO 2024035929 A3 WO2024035929 A3 WO 2024035929A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
reversal
sensitizers
insulin resistance
resistance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/030076
Other languages
French (fr)
Other versions
WO2024035929A2 (en
Inventor
Michael Karin
Li GU
Yahui ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2024035929A2 publication Critical patent/WO2024035929A2/en
Publication of WO2024035929A3 publication Critical patent/WO2024035929A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

This disclosure provides an isolated recombinant peptide comprising one or more of the FBP1 E1-E7 fragment or an equivalent thereof and a cell penetrating peptide, compositions and methods of using same to reverse insulin resistance in a subject in need thereof.
PCT/US2023/030076 2022-08-12 2023-08-11 Insulin sensitizers for reversal of insulin resistance Ceased WO2024035929A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263397615P 2022-08-12 2022-08-12
US63/397,615 2022-08-12

Publications (2)

Publication Number Publication Date
WO2024035929A2 WO2024035929A2 (en) 2024-02-15
WO2024035929A3 true WO2024035929A3 (en) 2024-03-21

Family

ID=89852424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/030076 Ceased WO2024035929A2 (en) 2022-08-12 2023-08-11 Insulin sensitizers for reversal of insulin resistance

Country Status (1)

Country Link
WO (1) WO2024035929A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014937A1 (en) * 2003-04-30 2012-01-19 Incyte Corporation Human Beta-Adrenergic receptor kinase polypeptide and methods
US20210060175A1 (en) * 2007-09-04 2021-03-04 Curevac Ag Methods of immunostimulation with complexes of rna and cationic carriers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120014937A1 (en) * 2003-04-30 2012-01-19 Incyte Corporation Human Beta-Adrenergic receptor kinase polypeptide and methods
US20210060175A1 (en) * 2007-09-04 2021-03-04 Curevac Ag Methods of immunostimulation with complexes of rna and cationic carriers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHAO LU: "A Noncanonical Role of Fructose-1, 6-Bisphosphatase 1 Is Essential for Inhibition of Notch1 in Breast Cancer", MOLECULAR CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 18, no. 5, 1 May 2020 (2020-05-01), US , pages 787 - 796, XP093152005, ISSN: 1541-7786, DOI: 10.1158/1541-7786.MCR-19-0842 *

Also Published As

Publication number Publication date
WO2024035929A2 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
WO2021108717A3 (en) Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
WO2006023922A3 (en) Compositions containing modified fullerenes
WO2006001023A3 (en) Chimeric proteins and uses thereof
EP2270140A3 (en) Variant lipolytic enzymes
HK1200322A1 (en) Immunobinders directed against sclerostin
BRPI0620806B8 (en) complex and composition comprising a peptide and a charge molecule, and use of said composition
WO2007035640A3 (en) Methods for reducing cd36 expression
WO2010144344A3 (en) Melanocortin receptor-specific peptides
WO2021007504A3 (en) Methods and compositions comprising reduced level of host cell proteins
EP4570814A3 (en) N-terminal capping modules of ankyrin repeat domains
TW200505989A (en) Solvent-containing compositions based on polychloroprene
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
CA3207182A1 (en) T cell therapy
WO2024035929A3 (en) Insulin sensitizers for reversal of insulin resistance
WO2020232141A3 (en) Compositions and methods for treating t cell exhaustion
WO2023194628A3 (en) Variants of ankyrin repeat domains
BRPI0517486A (en) acidulated fruit based composition and method of manufacturing fruit based composition
WO2005033275A3 (en) Methods for altering hematopoietic progenitor cell adhesion, differentiation, and migration
WO2023152568A3 (en) Compositions and methods for characterizing lung cancer by means of cell free rna
WO2007055823A3 (en) Gpcr expressing cell lines and antibodies
EP4438733A3 (en) Anti-fungal polypeptides
Laurence et al. A theoretical investigation of the preferred conformations of glutathione and its constituent amino acid residues
WO2024026468A3 (en) Methods and compositions regarding cyclic peptides for use with antibodies and antibody fragments
WO2023247968A3 (en) Modified amino acids and uses thereof
WO2008010096A3 (en) Method for preparing recombinant mycobacterial polypeptides in yeast and their use in diagnosis of mycobacterial related diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853392

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23853392

Country of ref document: EP

Kind code of ref document: A2